Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials.

Carretero-González A, Lora D, Manneh R, Lorente D, Castellano D, de Velasco G.

Clin Transl Oncol. 2020 Mar 20. doi: 10.1007/s12094-020-02334-6. [Epub ahead of print]

PMID:
32198642
2.

Association Between Second Progression-free Survival (PFS2) and Overall Survival in Metastatic Castration-resistant Prostate Cancer.

Lorente D, Castro E, Lozano R, Puente J, Romero-Laorden N, Rodríguez-Vida A, Lainez N, Villatoro R, Llácer C, Cattrini C, Hernández A, Domenech M, Zambrana F, Almagro E, Luque R, Martinez E, López-Campos F, Gonzalez B, Méndez-Vidal MJ, Medina A, Piulats JM, Olmos D; PROREPAIR-B Study Investigators.

Eur Urol. 2020 Mar 3. pii: S0302-2838(20)30135-4. doi: 10.1016/j.eururo.2020.02.025. [Epub ahead of print] No abstract available.

PMID:
32143923
3.

Robust association between vascular habitats and patient prognosis in glioblastoma: An international multicenter study.

Álvarez-Torres MDM, Juan-Albarracín J, Fuster-Garcia E, Bellvís-Bataller F, Lorente D, Reynés G, Font de Mora J, Aparici-Robles F, Botella C, Muñoz-Langa J, Faubel R, Asensio-Cuesta S, García-Ferrando GA, Chelebian E, Auger C, Pineda J, Rovira A, Oleaga L, Mollà-Olmos E, Revert AJ, Tshibanda L, Crisi G, Emblem KE, Martin D, Due-Tønnessen P, Meling TR, Filice S, Sáez C, García-Gómez JM.

J Magn Reson Imaging. 2019 Oct 26. doi: 10.1002/jmri.26958. [Epub ahead of print]

PMID:
31654541
4.

Association among the R.E.N.A.L. nephrometry score and clinical outcomes in patients with small renal masses treated with percutaneous contrast enhanced ultrasound radiofrequency ablation.

Konstantinidis C, Trilla E, Serres X, Montealegre C, Lorente D, Castellón R, Morote J.

Cent European J Urol. 2019;72(2):92-99. doi: 10.5173/ceju.2019.1833. Epub 2019 Jun 4.

5.

Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer.

Sumanasuriya S, Omlin A, Armstrong A, Attard G, Chi KN, Bevan CL, Shibakawa A, IJzerman MJ, De Laere B, Lolkema M, Lorente D, Luo J, Mehra N, Olmos D, Scher H, Soule H, Stoecklein NH, Terstappen LWMM, Waugh D, de Bono JS.

Eur Urol Oncol. 2018 Jun;1(2):151-159. doi: 10.1016/j.euo.2018.02.009. Epub 2018 May 15. Review.

6.

The role of negative magnetic resonance imaging: can we safely avoid biopsy in P.I.-R.A.D.S. 2 as in P.I.-R.A.D.S. 1?

Regis L, Celma A, Planas J, Lopez R, Roche S, Lorente D, Placer J, Trilla E, Morote J.

Scand J Urol. 2019 Feb;53(1):21-25. doi: 10.1080/21681805.2018.1551243. Epub 2019 Jan 10.

PMID:
30628520
7.

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.

Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodriguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D.

J Clin Oncol. 2019 Feb 20;37(6):490-503. doi: 10.1200/JCO.18.00358. Epub 2019 Jan 9.

PMID:
30625039
8.

The role of STAT3 protein as a prognostic factor in the clear cell renal carcinoma. Systematic review.

Lorente D, Trilla E, Meseguer A, Arevalo J, Nemours S, Planas J, Placer J, Celma A, Salvador C, Regis L, Schwartzmann I, Morote J.

Actas Urol Esp. 2019 Apr;43(3):118-123. doi: 10.1016/j.acuro.2018.08.003. Epub 2018 Nov 19. Review. English, Spanish.

PMID:
30466966
9.

Preoperative magnetic resonance imaging in predicting early continence recovery after robotic radical prostatectomy.

Regis L, Salazar A, Cuadras M, Miret E, Roche S, Celma A, Planas J, Lorente D, Placer J, Trilla E, Morote J.

Actas Urol Esp. 2019 Apr;43(3):137-142. doi: 10.1016/j.acuro.2018.07.003. Epub 2018 Nov 9. English, Spanish.

PMID:
30420112
10.

Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment.

Melian M, Lorente D, Aparici F, Juan O.

Thorac Cancer. 2018 Dec;9(12):1770-1773. doi: 10.1111/1759-7714.12873. Epub 2018 Oct 1.

11.

Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).

Romero-Laorden N, Lozano R, Jayaram A, López-Campos F, Saez MI, Montesa A, Gutierrez-Pecharoman A, Villatoro R, Herrera B, Correa R, Rosero A, Pacheco MI, Garcés T, Cendón Y, Nombela MP, Van de Poll F, Grau G, Rivera L, López PP, Cruz JJ, Lorente D, Attard G, Castro E, Olmos D.

Br J Cancer. 2018 Oct;119(9):1052-1059. doi: 10.1038/s41416-018-0123-9. Epub 2018 Aug 21.

12.

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.

Rescigno P, Lorente D, Dolling D, Ferraldeschi R, Rodrigues DN, Riisnaes R, Miranda S, Bianchini D, Zafeiriou Z, Sideris S, Ferreira A, Figueiredo I, Sumanasuriya S, Mateo J, Perez-Lopez R, Sharp A, Tunariu N, de Bono JS.

Eur Urol Oncol. 2018 May;1(1):71-77. doi: 10.1016/j.euo.2018.02.006.

13.

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.

Cortes J, Tamura K, DeAngelo DJ, de Bono J, Lorente D, Minden M, Uy GL, Kantarjian H, Chen LS, Gandhi V, Godin R, Keating K, McEachern K, Vishwanathan K, Pease JE, Dean E.

Br J Cancer. 2018 May;118(11):1425-1433. doi: 10.1038/s41416-018-0082-1. Epub 2018 May 16.

14.

Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.

Lorente D, Olmos D, Mateo J, Dolling D, Bianchini D, Seed G, Flohr P, Crespo M, Figueiredo I, Miranda S, Scher HI, Terstappen LWMM, de Bono JS.

Ann Oncol. 2018 Jul 1;29(7):1554-1560. doi: 10.1093/annonc/mdy172.

15.

Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations.

Salvador-Coloma C, Lorente D, Palanca S, Simarro J, Mancheño N, Sandoval J, Lahoz A, Juan Ó.

J Thorac Dis. 2018 Mar;10(3):1386-1393. doi: 10.21037/jtd.2018.02.30.

16.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

O'Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, Ejadi S, Piha-Paul SA, Stein MN, Abdul Razak AR, Dotti K, Santoro A, Cohen RB, Gould M, Saraf S, Stein K, Han SW.

PLoS One. 2017 Dec 28;12(12):e0189848. doi: 10.1371/journal.pone.0189848. eCollection 2017.

17.

A finite element-based machine learning approach for modeling the mechanical behavior of the breast tissues under compression in real-time.

Martínez-Martínez F, Rupérez-Moreno MJ, Martínez-Sober M, Solves-Llorens JA, Lorente D, Serrano-López AJ, Martínez-Sanchis S, Monserrat C, Martín-Guerrero JD.

Comput Biol Med. 2017 Nov 1;90:116-124. doi: 10.1016/j.compbiomed.2017.09.019. Epub 2017 Sep 28.

PMID:
28982035
18.

An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.

Diaz-Beveridge R, Bruixola G, Lorente D, Caballero J, Rodrigo E, Segura Á, Akhoundova D, Giménez A, Aparicio J.

Clin Transl Oncol. 2018 Mar;20(3):322-329. doi: 10.1007/s12094-017-1720-4. Epub 2017 Aug 11.

PMID:
28801777
19.

Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.

Lorente D, Ravi P, Mehra N, Pezaro C, Omlin A, Gilman A, Miranda M, Rescigno P, Kolinsky M, Porta N, Bianchini D, Tunariu N, Perez R, Mateo J, Payne H, Terstappen L, IJzerman M, Hall E, de Bono J.

Eur Urol Focus. 2018 Mar;4(2):235-244. doi: 10.1016/j.euf.2016.09.005. Epub 2016 Oct 10.

20.

Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer.

Lorente D, Fizazi K, Sweeney C, de Bono JS.

Eur Urol Focus. 2016 Dec;2(5):488-498. doi: 10.1016/j.euf.2016.10.008. Epub 2016 Nov 23. Review.

PMID:
28723514
21.

Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.

Mehra N, Sharp A, Lorente D, Dolling D, Sumanasuriya S, Johnson B, Dearnaley D, Parker C, de Bono J.

Clin Genitourin Cancer. 2017 Dec;15(6):678-684.e1. doi: 10.1016/j.clgc.2017.05.012. Epub 2017 May 10.

PMID:
28606735
22.

Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital.

Bianchini D, Lorente D, Rescigno P, Zafeiriou Z, Psychopaida E, O'Sullivan H, Alaras M, Kolinsky M, Sumanasuriya S, Sousa Fontes M, Mateo J, Perez Lopez R, Tunariu N, Fotiadis N, Kumar P, Tree A, Van As N, Khoo V, Parker C, Eeles R, Thompson A, Dearnaley D, de Bono JS.

Clin Genitourin Cancer. 2017 Oct;15(5):e801-e807. doi: 10.1016/j.clgc.2017.04.013. Epub 2017 Apr 26.

23.

Ultrasound-guided percutaneous radiofrequency ablation for treating small renal masses.

Trilla E, Konstantinidis C, Serres X, Lorente D, Planas J, Placer J, Salvador C, Celma A, Montealegre C, Morote J.

Actas Urol Esp. 2017 Oct;41(8):497-503. doi: 10.1016/j.acuro.2017.03.001. Epub 2017 Apr 28. English, Spanish.

PMID:
28457496
24.

Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.

Perez-Lopez R, Mateo J, Mossop H, Blackledge MD, Collins DJ, Rata M, Morgan VA, Macdonald A, Sandhu S, Lorente D, Rescigno P, Zafeiriou Z, Bianchini D, Porta N, Hall E, Leach MO, de Bono JS, Koh DM, Tunariu N.

Radiology. 2017 Apr;283(1):168-177. doi: 10.1148/radiol.2016160646. Epub 2016 Nov 22.

25.

Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.

Planas J, Celma A, Placer J, Cuadras M, Regis L, Gasanz C, Trilla E, Salvador C, Lorente D, Morote J.

Scand J Urol. 2016 Dec;50(6):425-428. Epub 2016 Sep 14.

PMID:
27628623
26.

Hormonal changes after localized prostate cancer treatment. Comparison between external beam radiation therapy and radical prostatectomy.

Planas J, Celma A, Placer J, Maldonado X, Trilla E, Salvador C, Lorente D, Regis L, Cuadras M, Carles J, Morote J.

Actas Urol Esp. 2016 Nov;40(9):549-555. doi: 10.1016/j.acuro.2016.02.010. Epub 2016 May 17. English, Spanish.

PMID:
27207596
27.

Systematic review of renal carcinoma prognostic factors.

Lorente D, Trilla E, Meseguer A, Planas J, Placer J, Celma A, Salvador C, Regis L, Morote J.

Actas Urol Esp. 2017 May;41(4):215-225. doi: 10.1016/j.acuro.2016.08.003. Epub 2016 Sep 20. Review. English, Spanish.

PMID:
27659130
28.

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.

Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, Danila DC, Flohr P, Crespo M, Figueiredo I, Miranda S, Baeten K, Molina A, Kheoh T, McCormack R, Terstappen LW, Scher HI, de Bono JS.

Eur Urol. 2016 Dec;70(6):985-992. doi: 10.1016/j.eururo.2016.05.023. Epub 2016 Jun 9.

29.

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.

Lorente D, Omlin A, Zafeiriou Z, Nava-Rodrigues D, Pérez-López R, Pezaro C, Mehra N, Sheridan E, Figueiredo I, Riisnaes R, Miranda S, Crespo M, Flohr P, Mateo J, Altavilla A, Ferraldeschi R, Bianchini D, Attard G, Tunariu N, de Bono J.

Clin Genitourin Cancer. 2016 Dec;14(6):485-493. doi: 10.1016/j.clgc.2016.04.016. Epub 2016 May 5.

30.

Utility of the RENAL index -Radius; Exophytic/endophytic; Nearness to sinus; Anterior/posterior; Location relative to polar lines- in the management of renal masses.

Konstantinidis C, Trilla E, Lorente D, Morote J.

Actas Urol Esp. 2016 Dec;40(10):601-607. doi: 10.1016/j.acuro.2016.04.007. Epub 2016 May 18. Review. English, Spanish.

PMID:
27209331
31.

Economic growth and energy regulation in the environmental Kuznets curve.

Lorente DB, Álvarez-Herranz A.

Environ Sci Pollut Res Int. 2016 Aug;23(16):16478-94. doi: 10.1007/s11356-016-6773-3. Epub 2016 May 11.

PMID:
27164892
32.

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.

Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, Figueiredo I, Zafeiriou Z, Rescigno P, de Bono JS, Plymate SR.

Eur Urol. 2016 Oct;70(4):599-608. doi: 10.1016/j.eururo.2016.03.049. Epub 2016 Apr 23.

33.

Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.

Rescigno P, Lorente D, Bianchini D, Ferraldeschi R, Kolinsky MP, Sideris S, Zafeiriou Z, Sumanasuriya S, Smith AD, Mehra N, Jayaram A, Perez-Lopez R, Mateo J, Parker C, Dearnaley DP, Tunariu N, Reid A, Attard G, de Bono JS.

Eur Urol. 2016 Nov;70(5):724-731. doi: 10.1016/j.eururo.2016.02.055. Epub 2016 Mar 7.

34.

Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer.

Perez-Lopez R, Lorente D, Blackledge MD, Collins DJ, Mateo J, Bianchini D, Omlin A, Zivi A, Leach MO, de Bono JS, Koh DM, Tunariu N.

Radiology. 2016 Jul;280(1):151-60. doi: 10.1148/radiol.2015150799. Epub 2016 Jan 25.

PMID:
26807894
35.

CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer.

Mehra N, Zafeiriou Z, Lorente D, Terstappen LW, de Bono JS.

Clin Cancer Res. 2015 Nov 15;21(22):4992-5. doi: 10.1158/1078-0432.CCR-14-3129.

36.

A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer.

Wilbaux M, Tod M, De Bono J, Lorente D, Mateo J, Freyer G, You B, Hénin E.

CPT Pharmacometrics Syst Pharmacol. 2015 May;4(5):277-85. doi: 10.1002/psp4.34. Epub 2015 Apr 24.

37.

Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.

Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava-Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, Yap TA, Banerji U, Gasi Tandefelt D, Turner N, Attard G, de Bono JS.

Clin Cancer Res. 2015 Oct 15;21(20):4586-96. doi: 10.1158/1078-0432.CCR-15-0584. Epub 2015 Jun 17.

38.

Sequencing of agents in castration-resistant prostate cancer.

Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G.

Lancet Oncol. 2015 Jun;16(6):e279-92. doi: 10.1016/S1470-2045(15)70033-1. Epub 2015 May 27. Review.

PMID:
26065613
39.

Multimodality Treatment of Pediatric and Adult Patients With Ewing Sarcoma: A Single-institution Experience.

Diaz-Beveridge R, Lorente D, Torres B, Cañete A, Rodrigo E, Bruixola G, Berlanga P, Reche E, Montalar J, Verdeguer A, Aparicio J.

J Pediatr Hematol Oncol. 2015 Jul;37(5):e278-84. doi: 10.1097/MPH.0000000000000339.

PMID:
25929608
40.

What have we learned from exceptional tumour responses?: Review and perspectives.

Mehra N, Lorente D, de Bono JS.

Curr Opin Oncol. 2015 May;27(3):267-75. doi: 10.1097/CCO.0000000000000182. Review.

PMID:
25811347
41.

The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials.

Kumar R, Geuna E, Michalarea V, Guardascione M, Naumann U, Lorente D, Kaye SB, de Bono JS.

Br J Cancer. 2015 Mar 31;112(7):1157-65. doi: 10.1038/bjc.2015.67.

42.

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.

Crespo M, van Dalum G, Ferraldeschi R, Zafeiriou Z, Sideris S, Lorente D, Bianchini D, Rodrigues DN, Riisnaes R, Miranda S, Figueiredo I, Flohr P, Nowakowska K, de Bono JS, Terstappen LW, Attard G.

Br J Cancer. 2015 Mar 31;112(7):1166-74. doi: 10.1038/bjc.2015.63.

43.

Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Lorente D, Mateo J, Zafeiriou Z, Smith AD, Sandhu S, Ferraldeschi R, de Bono JS.

Nat Rev Urol. 2015 Jan;12(1):37-47. doi: 10.1038/nrurol.2014.345. Review.

PMID:
25563847
44.

Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer.

Pezaro C, Omlin A, Perez-Lopez R, Mukherji D, Attard G, Bianchini D, Lorente D, Parker C, Dearnaley D, de Bono JS, Sohaib A, Tunariu N.

Clin Radiol. 2015 Apr;70(4):359-65. doi: 10.1016/j.crad.2014.05.104. Epub 2014 Dec 30.

PMID:
25555314
45.

Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.

Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R, Bahl A, Shen L, Su Z, Sartor O, de Bono JS.

Ann Oncol. 2015 Apr;26(4):750-5. doi: 10.1093/annonc/mdu587. Epub 2014 Dec 23.

46.

A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer.

Venkitaraman R, Lorente D, Murthy V, Thomas K, Parker L, Ahiabor R, Dearnaley D, Huddart R, De Bono J, Parker C.

Eur Urol. 2015 Apr;67(4):673-9. doi: 10.1016/j.eururo.2014.10.004. Epub 2014 Oct 16.

PMID:
25457497
47.

PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J, Altavilla A, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono J.

Eur Urol. 2015 Apr;67(4):795-802. doi: 10.1016/j.eururo.2014.10.027. Epub 2014 Nov 4.

48.

Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone.

Lorente D, Omlin A, Ferraldeschi R, Pezaro C, Perez R, Mateo J, Altavilla A, Zafeirou Z, Tunariu N, Parker C, Dearnaley D, Gillessen S, de Bono J, Attard G.

Br J Cancer. 2014 Dec 9;111(12):2248-53. doi: 10.1038/bjc.2014.531. Epub 2014 Oct 14.

49.

Tumor clone dynamics in lethal prostate cancer.

Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel JS, Pezaro C, Omlin A, Rodrigues DN, Flohr P, Tunariu N, S de Bono J, Demichelis F, Attard G.

Sci Transl Med. 2014 Sep 17;6(254):254ra125. doi: 10.1126/scitranslmed.3009448.

50.

Effects of holmium laser enucleation of the prostate on sexual function.

Placer J, Salvador C, Planas J, Trilla E, Lorente D, Celma A, López MÁ, Morote J.

J Endourol. 2015 Mar;29(3):332-9. doi: 10.1089/end.2014.0502. Epub 2014 Oct 21.

PMID:
25133981

Supplemental Content

Loading ...
Support Center